Latest Breaking News On - Olga guyette - Page 5 : comparemela.com

Peer-Reviewed Results of Haemonetics' Improving Plasma Collection (IMPACT) Trial Published in the Journal TRANSFUSION

Share this article Share this article BOSTON, April 29, 2021 /PRNewswire/  Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that the full peer-reviewed results of the IMproving PlasmA CollecTion (IMPACT) trial have been published in TRANSFUSION, the prime journal for transfusion medicine related research. The publication expands upon the IMPACT trial data presented in October 2020 in a plenary session at the AABB conference. IMPACT, a multicenter, prospective and double-blinded study, is one of the largest randomized controlled trials of plasmapheresis. The trial involved 3,443 donors who underwent 23,137 plasma donations.

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2021 Results: May 13, 2021

Share this article Share this article BOSTON, April 23, 2021 /PRNewswire/  Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2021 financial results at 6:00 am EDT on Thursday, May 13, 2021. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on May 13, 2021.  The call can be accessed with the following information: U.S. / Canada toll free (877) 848-8880; International (716) 335-9512 Conference ID required for access: 8694785 A live webcast of the call can be accessed on Haemonetics investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/xqyzme3t

Haemonetics Provides Update On U.S. Plasma Business

Haemonetics Announces Proposed Convertible Senior Notes Offering

Haemonetics Announces Proposed Convertible Senior Notes Offering News provided by Share this article Share this article BOSTON, March 1, 2021 /PRNewswire/  Haemonetics Corporation ( Haemonetics ) (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $425,000,000 aggregate principal amount of Convertible Senior Notes due 2026 (the notes ) in a private offering (the offering ) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act ). Haemonetics also expects to grant the initial purchasers of the notes an option to purchase up to an additional $63,750,000 aggregate principal amount of the notes. The notes will be senior, unsecured obligations of Haemonetics, will accrue interest payable semi-annually in arrears, and will mature on March 1, 2026, unless earlier repurchased, redeemed or converted.  Noteholders will have the right to convert their notes in certain circumstanc

Haemonetics Corp (HAE) Q3 2021 Earnings Call Transcript

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Haemonetics Corporation Q3 2021 Earnings Conference Call. [Operator Instructions] Please be advised that today s conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today; Olga Guyette, Director, Investor Relations. Please go ahead, ma am. Olga Guyette Director-Investor Relations Thank you. Good morning, everyone. Thank you for joining us for Haemonetics third quarter fiscal 21 conference call and webcast. I m joined today by Chris Simon, our CEO; Stewart Strong, President of the Hospital Business Unit; and Bill Burke, our CFO. This morning, we posted our third quarter and year-to-date fiscal 21 results to our Investor Relations website, including the analytical tables with the information that we ll refer to on this call, and an investor presentation on the pending Cardiva transaction. Additionally, we provided a complete P&L, balance